Cited by 25Attention Deficit Hyperactivity DisorderPharmaceutical studies and practicesDevelopmental and Educational Neuropsychology

Neurocognitive effects of switching from methylphenidate‐IR to OROS‐methylphenidate in children with ADHD

Kim, Yeni, Shin, Min‐Sup, Kim, Jae‐Won, Yoo, Hee‐Jung, Cho, Soo‐Churl, Kim, Boong‐Nyun·2009·Human Psychopharmacology: Clinical and Experimental

Abstract

Objectives: This study evaluated neurocognitive changes after switching from immediate release forms of methylphenidate (MPH‐IR) to osmotic release oral system methylphenidate (OROS‐MPH). Methods: 102 children with attention‐deficit/hyperactivity disorder (ADHD) participated in an open label, 28 day trial, performing neurocognitive test at baseline and at 28 days after the switch from MPH‐IR to OROS‐MPH. Results: There were significant improvements in the commission error and the reaction time of both visual and auditory continuous performance tests (CPTs) at 28 days after switching from MPH‐IR to OROS‐MPH. A positive correlation was observed between the improvement in parent/caregiver‐rated IOWA Conners total score (Δ IOWA) and the reduction in commission error (r = 0.3, p = 0.001) and reduction in reaction time variability (r = 0.3, p = 0.006) of visual CPT. In a linear regression model, the change in parent/caregiver‐rated IOWA Conners scale total scores were significant predictors of change in commission error (β = 0.3, p = 0.005, CI = 0.4–2.3, adjusted R2 = 0.12) and RT variability (β = 0.3, p = 0.004, CI = 0.5–2.4, adjusted R2 = 0.09) of visual CPT. Conclusions: These data suggest that MPH‐IR may be successfully switched to OROS‐MPH treatment with associated improvements in neurocognitive performance. Large‐scale controlled trials are needed to replicate these findings. Copyright © 2009 John Wiley & Sons, Ltd.

Integrity signals

Registry

Crossref · 10.1002/hup.1010

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • OROS methylphenidate lessens ADHD symptoms throughout the day and has greater adherence, thought associated with convenience of once-daily dosing.

    “Research has continued to suggest that osmotic-release oral system (OROS) methylphenidate lessens ADHD symptoms throughout the day and has greater adherence, thought to be associated with the convenience of once-daily dosing [39-41].”

    From Advances in understanding and treating ADHD (2011) · cites this paper as [39]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Kim, Y., Shin, M., Kim, J., Yoo, H., Cho, S., & Kim, B.
Affiliations
Seoul National University (KR)
Corresponding author
Kim, Boong‐Nyun
Venue
Human Psychopharmacology: Clinical and Experimental
Publisher
Wiley
Published
2009-02-18
Volume
24
Issue
2
Pages
95-102
ISSN
  • 0885-6222 (ISSN-L)
  • 1099-1077
OpenAlex
W2161957029
Cited by
25
References
36
Citations by year
2026: 1 · 2025: 2 · 2023: 1 · 2022: 1 · 2019: 1 · 2018: 1 · 2017: 2 · 2014: 2 · 2013: 4 · 2012: 1
FWCI
2.06
Type
journal article
Language
en
Open access
closed
Locations
  • Human Psychopharmacology Clinical and Experimental (publishedVersion)
  • PubMed (publishedVersion)
  • Seoul National University Open Repository (Seoul National University) (submittedVersion)
Funders
Janssen Pharmaceuticals
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
  • Social Sciences › Psychology › Neuropsychology and Physiological Psychology › Developmental and Educational Neuropsychology
Keywords
methylphenidate, OROS methylphenidate, immediate-release methylphenidate, attention deficit hyperactivity disorder, children, drug switching, neuropsychological performance, continuous performance test, commission errors, reaction time variability, parent ratings
MeSH terms
Administration, Oral, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Child, Cognition Disorders, Delayed-Action Preparations, Female, Humans, Male, Methylphenidate, Neuropsychological Tests, Reaction Time, Linear Models

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review